Evaluation of the efficacy and safety of levalbuterol in subjects with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 3, Issue 3, 2006, Pages 125-132

  Donohue, James ^a   Parsey, Merdad ^b   Andrews, Charles ^c   D'Urzo, Tony ^d   Sharma, Satyendra ^e   Schaefer, Kendyl ^b   Claus, Raymond ^b   Baumgartner, Rudolf ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c Diagnostics Research Group   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bronchodilator; COPD; Levalbuterol; Racemic albuterol

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; PLACEBO; SALBUTAMOL; XANTHINE DERIVATIVE;

ACCIDENTAL INJURY; ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; EDEMA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEBULIZATION; NEBULIZER; NERVOUSNESS; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SIDE EFFECT; SPIROMETRY; THORAX PAIN; TREMOR; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 33746881047     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550600829190     Document Type: Article

References (21)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349:1498-1504.
2. Michaud CM, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA 2001; 285:535-539.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276. GOLD Guidelines 2003 at 〈www.goldcopd.com〉
4. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004; 113:503-510.
5. Ameredes BT, Calhoun WJ. Modulation of GM-CSF-release by enantiomers of β-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005; 116:65-72.
6. Cho SH, Hartleroad JY, Oh CK. (S)-Albuterol increases the production of histamine and IL-4 mast cells. Int Arch Allergy Immunol 2001; 124:478-484.
7. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of t-cell function by (R)- and (S)-isomers of albuterol: antiinflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002; 108:449-454.
8. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124:844-849.
9. Bestall JC , Paul EA, Garrod R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-586.
10. Mahler D, Rosiello R, Harver A, Lentine T, McGovern J, Daubenspeck J. Comparison of clinical dyspnea ratings and psychological measurements of respiratory sensation in obstructive pulmonary disease. Am Rev Respir Dis 1987; 135:1229-1233.
11. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
12. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127:335-371.
13. The Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105:1411-1419.
14. The Combivent Inhalation Aerosol Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112:1514-1521.
15. Santello NC, Zhang J, Seidenberg B, Seidenberg, Reiss TF, Barber BL. What are the minimal important changes for asthma measures in a clinical trial. Eur Respir J 1999; 14:23-27.
16. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731-736.
17. Nowak R, Emerman C, Hanrahan JP, Parsey MV, Hanania NA, Schaefer K, Baumgartner RA. A comparison of levalbuterol and racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emer Med 2006; 24:259-267.
18. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422.
19. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.
20. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1613.
21. Kim S, Emerman CL, Cydulka RK, Rowe BH, Clark S, Camargo CA. Prospective multicenter study of relapse following emergency department treatment of COPD exacerbation. Chest 2004; 125:473-481.